Eagle Pharmaceuticals (EGRX) Earns Daily Media Sentiment Rating of 0.14

News headlines about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.1992503958581 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) traded up $1.87 during mid-day trading on Friday, reaching $55.30. The company’s stock had a trading volume of 306,000 shares, compared to its average volume of 348,552. The company has a quick ratio of 3.76, a current ratio of 5.30 and a debt-to-equity ratio of 0.26. Eagle Pharmaceuticals has a 12-month low of $45.05 and a 12-month high of $97.15. The company has a market capitalization of $797.26, a P/E ratio of 8.43 and a beta of 1.23.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.51 by ($0.18). The company had revenue of $50.10 million during the quarter, compared to the consensus estimate of $52.52 million. Eagle Pharmaceuticals had a net margin of 36.95% and a return on equity of 62.60%. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.80 EPS. equities analysts forecast that Eagle Pharmaceuticals will post 3.59 EPS for the current year.

Eagle Pharmaceuticals declared that its Board of Directors has approved a share repurchase plan on Wednesday, August 9th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the specialty pharmaceutical company to buy up to 13.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Several analysts have weighed in on EGRX shares. Royal Bank of Canada set a $94.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, July 16th. Piper Jaffray Companies set a $118.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 25th. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub downgraded Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Finally, Mizuho lowered their price objective on Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating for the company in a research report on Wednesday, September 6th. Three analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Eagle Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $62.33.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/11/11/eagle-pharmaceuticals-egrx-earns-daily-media-sentiment-rating-of-0-14.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply